Global Nanopharmaceutical Drugs Market is Expected to Reach $79.29 Bn by 2026

Wednesday 5 December 2018, Amsterdam

Big pharma companies rely on bestselling drugs for maximum revenue generation. The patent protection allows the pharma company to sell the drugs at high profit margin, for example the Pfizer’s drug known as Lipitor, accounts for about $13 bn of Pfizer’s revenues. Many blockbuster drugs are going off patent, drug manufacturers are facing challenges to develop novel research and development strategies, involving miniaturization through various techniques including nanotechnology.

The introduction of nanotechnology in medicines has revolutionized the pharmaceutical industry. With the advancement in the Nano pharmaceutical industry, the number of patent filings has dramatically increased. Pharmaceutical companies have developed new strategies & techniques to re-patent drugs which are on the way to expiration by modifying them with the help of nanotechnology. Nanodrugs offers a promising potential in terms of revenue growth.

The nanopharmaceuticals have broach range of application and are used in imaging, diagnostics and therapeutics and possess full potential to dominate the pharmaceutical market. The introduction of nanomedicine will alter the landscape of medicine and will drastically improve a patient’s quality of life and reduce healthcare costs.

According to the latest report, titled 'Global Nanopharmaceutical Drugs Market – Analysis and Forecast (2018-2026)’, the global nanopharmaceutical drug market is valued $40.37 billion in 2017 and is expected to reach $79.29 billion by 2026. The major factor driving the growth of this market, are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population. Further, the increasing insurance coverage and reimburesement policies in the developed markets such as the U.S., Japan, Germany, and the U.K. are the key drivers for the growth of the nanopharmaceutical drugs market.

Companies Mentioned in the Report:

• AbbVie Inc.
• AMAG Pharmaceuticals
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• CELGENE CORPORATION
• Gilead Sciences, Inc.
• JOHNSON & JOHNSON
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Hoffmann-La Roche AG
• Sanofi S.A
• Shire Plc.
• Teva Pharmaceuticals Industries Limited

Key Questions Addressed in the Report:

• How did the Nanopharmaceutical Drugs market evolve, and what is its scope in the future?
• What are the major market drivers, challenges, and opportunities in the global Nanopharmaceutical Drugs market?
• What are the key developmental strategies that are implemented by the key players to sustain in this market?
• How nanopharmaceutical Drugs is superior that conventional drugs?
• How will the investments by public and private companies and government organizations affect the global nanopharmaceutical drugs market?
• What was the market size of the leading segments and sub-segments of the global nanopharmaceutical drugs market in 2017?
• How will the industry evolve during the forecast period 2018-2026?
• What will be the growth rate of the nanopharmaceutical drugs during the forecast period?
• How will each segment of the global nanopharmaceutical drugs market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2026?
• Which drug carrier segment, application segment and distribution channel is expected to register the highest CAGR for the nanopharmaceutical drugs market?
• What is the market size of nanopharmaceutical drugs in different countries of the world?
• Which geographical region will contribute to the highest sales of nanopharmaceutical drugs?
• Who are the key players in the nanopharmaceutical drugs market, and what are their contributions?